Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! 

China Clinical Trials 2017

Analysis of IND and NDA applications and approvals in China 2011-2017

Download free report on life science investment in China

Week in Review: iCarbonX "Ecosystem" Invests $400 Million in Seven Companies

publication date: Jan 7, 2017

iCarbonX, the Shenzhen big data/artificial intelligence health company, formed The Digital Life Alliance with seven outside life science companies, complete with a total investment of nearly $400 million from the iCarbonX ecosystem; Ascletis of Hangzhou completed a $100 million series B financing to build a sales force and acquire additional liver disease drugs; Nanjing Frontier Biotech, which is developing a novel AIDS treatment, raised $43 million in a Series C round; MabSpace of Suzhou will collaborate with San Diego's Ambrx to discover multiple novel antibody drug conjugates; Lee's Pharm in-licensed China rights to a clinic-ready treatment for wet age-related macular degeneration from TOT Biopharma of Suzhou; BIT Group of Germany officially opened EMD Shenzhen, a Joint Venture with EDAN Instruments that offers CMO services for IVD products; Taiwan's TLC reported positive top-line results from the Phase I/II trial of TLC599, a sustained release corticosteroid; and Beijing's Yisheng Biopharma was granted US Orphan Drug designation for a novel PIKA rabies vaccine. More details....

Stock Symbols: (HK: 950) (TT: 4152)

Share this with colleagues:  

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China